

Philipp Ivanyi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3766192/philipp-ivanyi-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

167
papers

2,466
citations

26
h-index

42
g-index

197
ext. papers

2,706
ext. citations

3.8
avg, IF

4.34
L-index

#	Paper	IF	Citations
167	Expression of Prostate-specific Membrane Antigen (PSMA) in Papillary Renal Cell Carcinoma - Overview and Report on a Large Multicenter Cohort.. <i>Journal of Cancer</i> , 2022 , 13, 1706-1712	4.5	0
166	Prognostic Impact of Lymphnode Metastases in Patients with Metastatic Renal Cell Carcinoma. <i>Kidney Cancer</i> , 2021 , 1-8	0.6	
165	Protective measures for patients with advanced cancer during the Sars-CoV-2 pandemic: Quo vadis?. <i>Clinical and Experimental Metastasis</i> , 2021 , 38, 257-261	4.7	3
164	Characterization of PD-1 and PD-L1 Expression in Papillary Renal Cell Carcinoma: Results of a Large Multicenter Study. <i>Clinical Genitourinary Cancer</i> , 2021 , 19, 53-59.e1	3.3	3
163	Prognostic role of docetaxel-induced reduction of free testosterone serum levels in metastatic prostate cancer patients.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 144-144	2.2	
162	Role of free testosterone serum levels during salvage chemotherapy with carboplatin plus weekly docetaxel in patients with docetaxel-refractory, metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 145-145	2.2	
161	Checkpoint inhibitor-induced autoimmune central nervous system disorder in patients with metastatic melanoma and Hodgkin lymphoma. <i>Clinical and Experimental Neuroimmunology</i> , 2021 , 12, 127-134	0.4	0
160	Impact of sarcopenia in advanced and metastatic soft tissue sarcoma. <i>International Journal of Clinical Oncology</i> , 2021 , 26, 2151-2160	4.2	2
159	Prognostic role of docetaxel-induced suppression of free testosterone serum levels in metastatic prostate cancer patients. <i>Scientific Reports</i> , 2021 , 11, 16457	4.9	
158	Checkpoint Inhibition for Metastatic Urothelial Carcinoma After Chemotherapy-Real-World Clinical Impressions and Comparative Review of the Literature. <i>Frontiers in Oncology</i> , 2020 , 10, 808	5.3	4
157	Revolution in der Systemtherapie des metastasierten Nierenzellkarzinoms. <i>Der Nephrologe</i> , 2020 , 15, 12-19	0.1	
156	Lower-dosing ponatinib in pre-treated GIST: Results of the POETIG phase II trial.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 11536-11536	2.2	2
155	A randomized phase II trial comparing switch to nivolumab with TKI continuation after 12 weeks of TKI induction therapy in metastatic renal cell carcinoma patients (NIVOSWITCH).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 678-678	2.2	2
154	Hepatic toxicity during regorafenib treatment in patients with metastatic gastrointestinal stromal tumors. <i>Molecular and Clinical Oncology</i> , 2020 , 13, 72	1.6	2
153	A randomized phase II study of nivolumab plus ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST).. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS5103-TPS5103	2.2	2
152	Which patients with pre-treated locally advanced or metastatic sarcoma benefit most from trabectedin treatment: First results of a retrospective study of the German Interdisciplinary Sarcoma Group (GISG-14 - ReTraSarc).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 11554-11554	2.2	
151	Survival in metastatic renal cell carcinoma (mRCC) patients over two decades: Does age matter?. <i>Journal of Clinical Oncology</i> , 2020 , 38, e17103-e17103	2.2	

150	Consensus paper: current state of first- and second-line therapy in advanced clear-cell renal cell carcinoma. <i>Future Oncology</i> , 2020 , 16, 2307-2328	3.6	9
149	Extracorporeal portosystemic shunt in secondary Budd-Chiari syndrome. <i>Journal of Hepatology</i> , 2020 , 73, 974-976	13.4	1
148	Randomized Comparison of Pazopanib and Doxorubicin as First-Line Treatment in Patients With Metastatic Soft Tissue Sarcoma Age 60 Years or Older: Results of a German Intergroup Study. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3555-3564	2.2	26
147	Systemic treatment of advanced/metastatic renal cell carcinoma in the context of SARS-CoV-2 pandemic: recommendations from the interdisciplinary working group for renal tumors (IAG-N). <i>Journal of Cancer Research and Clinical Oncology</i> , 2020 , 146, 3075-3078	4.9	2
146	Diagnosis and Differential Diagnosis of Neurological Adverse Events during Immune Checkpoint Inhibitor Therapy. <i>Journal of Oncology</i> , 2020 , 2020, 8865054	4.5	1
145	Neurological Immune Related Adverse Events Associated with Nivolumab, Ipilimumab, and Pembrolizumab Therapy-Review of the Literature and Future Outlook. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	57
144	Treatment with metformin is associated with a prolonged survival in patients with hepatocellular carcinoma. <i>Liver International</i> , 2019 , 39, 714-726	7.9	28
143	Immunonkologische Therapie vs. Chemotherapie –aktuelle Konzepte bei Hals-Kopf-Tumoren. <i>Tumor Diagnostik Und Therapie</i> , 2019 , 40, 98-101	0.1	
142	Sarcoid-Like Lesions Mimicking Pulmonary Metastasis: A Case Series and Review of the Literature. <i>Oncology Research and Treatment</i> , 2019 , 42, 382-386	2.8	1
141	Systemtherapie des Nierenzellkarzinoms. <i>Onkologe</i> , 2019 , 25, 517-522	0.1	1
140	Piwi-like 1 protein expression is a prognostic factor for renal cell carcinoma patients. <i>Scientific Reports</i> , 2019 , 9, 1741	4.9	6
139	Renal cell carcinoma in kidney transplant recipients: descriptive analysis and overview of a major German transplant center. <i>Future Oncology</i> , 2019 , 15, 3739-3750	3.6	2
138	A randomized phase II study of durvalumab and tremelimumab compared to doxorubicin in patients with advanced or metastatic soft tissue sarcoma (MEDISARC, AIO-ST5 0415).. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS11075-TPS11075	2.2	1
137	Sarcopenia (SMI(+)) in patients (pts) with advanced or metastatic soft tissue sarcoma (a/mSTS): Potential parameter for risk prediction during multimodal therapy (MT)?.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 11069-11069	2.2	
136	Bevacizumab-associated glomerular microangiopathy. <i>Modern Pathology</i> , 2019 , 32, 684-700	9.8	16
135	Treatment-related hemophagocytic lymphohistiocytosis secondary to checkpoint inhibition with nivolumab plus ipilimumab. <i>European Journal of Cancer</i> , 2018 , 93, 150-153	7.5	26
134	Active surveillance and deferred medical treatment (ASDT) in metastatic renal cell carcinoma (mRCC): Update of a single center experience and efficacy of medical treatment.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 4581-4581	2.2	
133	Prognostic value of testosterone levels during chemotherapy with carboplatin plus weekly docetaxel in metastatic castration- and docetaxel-resistant prostate cancer (mDRPC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, e17069-e17069	2.2	

132	Association of multimodality treatment (MT) with improved overall survival (OS) in patients (pts) with advanced/metastatic soft tissue sarcoma (a/m STS).. <i>Journal of Clinical Oncology</i> , 2018 , 36, e23566-e23566	2.2	2
131	Prognostic impact of PD-1 and its ligands in renal cell carcinoma. <i>Medical Oncology</i> , 2017 , 34, 99	3.7	14
130	CT patterns of organizing pneumonia in patients treated with VEGF/mTOR inhibitors for metastatic renal cell cancer: an observational study. <i>Acta Radiologica Open</i> , 2017 , 6, 2058460117694216	1.2	2
129	PD-L2: A prognostic marker in chromophobe renal cell carcinoma?. <i>Medical Oncology</i> , 2017 , 34, 71	3.7	12
128	c-Met in chromophobe renal cell carcinoma. <i>Medical Oncology</i> , 2017 , 34, 15	3.7	4
127	Impact of alpha 1-antitrypsin deficiency and prior augmentation therapy on patients' survival after lung transplantation. <i>European Respiratory Journal</i> , 2017 , 50,	13.6	6
126	Therapy of Treatment-Related Hypertension in Metastatic Renal-Cell Cancer Patients Receiving Sunitinib. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 280-290.e3	3.3	6
125	c-Met Onkogen bei Nierenzellkarzinomen. <i>Tumor Diagnostik Und Therapie</i> , 2017 , 38, 381-385	0.1	
124	Predictive Factors for Second-Line Therapy in Metastatic Renal Cell Carcinoma: A Retrospective Analysis. <i>Journal of Kidney Cancer and VHL</i> , 2017 , 4, 8-15	1.4	4
123	Prognostic value of free testosterone (FT) levels during chemotherapy with carboplatin plus weekly docetaxel in metastatic castration- and docetaxel-resistant prostate cancer (mDRPC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 5039-5039	2.2	
122	Intratumoral expression of programmed death ligand 1 (PD-L1) in patients with clear cell renal cell carcinoma (ccRCC). <i>Medical Oncology</i> , 2016 , 33, 80	3.7	27
121	Prognostic significance of free testosterone levels during chemotherapy with carboplatin plus docetaxel (CD) in metastatic castration- and docetaxel-resistant prostate cancer (mDRPC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 5029-5029	2.2	1
120	Active surveillance (AS) in the management of patients (pts) with metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, e16070-e16070	2.2	1
119	Does the onset of bone metastasis in sunitinib-treated renal cell carcinoma patients impact the overall survival?. <i>World Journal of Urology</i> , 2016 , 34, 909-15	4	4
118	Do programmed death 1 (PD-1) and its ligand (PD-L1) play a role in patients with non-clear cell renal cell carcinoma?. <i>Medical Oncology</i> , 2016 , 33, 59	3.7	20
117	PD-1/PD-L1 expression in chromophobe renal cell carcinoma: An immunological exception?. <i>Medical Oncology</i> , 2016 , 33, 120	3.7	14
116	TEMHEAD: a single-arm multicentre phase II study of temsirolimus in platin- and cetuximab refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) of the German SCCHN Group (AIO). <i>Annals of Oncology</i> , 2015 , 26, 561-7	10.3	46
115	Interstitial lung disease during targeted therapy in metastatic renal cell carcinoma: a case series from three centres. <i>Medical Oncology</i> , 2014 , 31, 147	3.7	8

114	High cut-off dialysis as a salvage therapy option in high-dose methotrexate chemotherapy?. <i>Annals of Hematology</i> , 2014 , 93, 1053-5	3	1
113	Confusion of therapeutic approaches. <i>Deutsches A&#x0308;rzteblatt International</i> , 2014 , 111, 405	2.5	
112	Prognostic value of free testosterone (FT) levels during salvage chemotherapy with carboplatin plus weekly docetaxel in metastatic castration- and docetaxel-resistant prostate cancer (mDRPC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5084-5084	2.2	
111	Late onset of bone metastases as a prognostic parameter in metastatic renal cell cancer (mRCC): A single-center experience in 82 mRCC patients treated with sunitinib.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 523-523	2.2	
110	Salvage chemotherapy with carboplatin plus weekly docetaxel in patients (pts) with castration- and docetaxel-resistant prostate cancer (DRPC): Associations of patient and disease characteristics with overall survival (OS).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 75-75	2.2	
109	Phenotyping established chronic lung allograft dysfunction predicts extracorporeal photopheresis response in lung transplant patients. <i>American Journal of Transplantation</i> , 2013 , 13, 911-918	8.7	66
108	Reconstitution and phenotype of Tregs in CMV reactivating patients following allogeneic hematopoietic stem cell transplantation. <i>Immunological Investigations</i> , 2013 , 42, 18-35	2.9	8
107	Interstitial lung diseases during treatment with sunitinib or mTOR inhibitors in metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 420-420	2.2	
106	Human regulatory T cells of G-CSF mobilized allogeneic stem cell donors qualify for clinical application. <i>PLoS ONE</i> , 2012 , 7, e51644	3.7	21
105	Temsirolimus Is Active in Refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN) Failing Platinum-Based Chemotherapy and Cetuximab: Efficacy and Toxicity Data from the Phase II Temhead Study. <i>Annals of Oncology</i> , 2012 , 23, ix336-ix337	10.3	4
104	Isolation strategies of regulatory T cells for clinical trials: phenotype, function, stability, and expansion capacity. <i>Experimental Hematology</i> , 2011 , 39, 1152-60	3.1	41
103	Response of renal lesions during systemic treatment with sunitinib in patients with metastatic renal cell carcinoma: a single center experience with 14 patients. <i>World Journal of Urology</i> , 2011 , 29, 355-60	4	9
102	Carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer (DRPC).. <i>Journal of Clinical Oncology</i> , 2011 , 29, 172-172	2.2	
101	Regulatory T Cells of G-CSF Mobilized Stem Cell Donors Qualify for Clinical Applications,. <i>Blood</i> , 2011 , 118, 4055-4055	2.2	
100	Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinib. <i>BMC Cancer</i> , 2010 , 10, 695	4.8	56
99	Self-expanding metallic stent placement with laryngeal mask in lung transplant recipients. <i>Transplantation Proceedings</i> , 2010 , 42, 4595-9	1.1	4
98	Carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer. <i>World Journal of Urology</i> , 2010 , 28, 391-8	4	15
97	Treatment with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma is associated with drug-induced hyperparathyroidism: a single center experience in 59 patients. <i>World Journal of Urology</i> , 2010 , 28, 311-7	4	1

96	Pre T-cell receptor alpha (pTalpha) expression patterns and functional analysis in human T-cell lymphoblastic leukemia. <i>Cellular Oncology</i> , 2010 , 32, 101-8		1
95	Allo-Antigens and Antigenic Factors of Human Leukocytes: A Hypothesis. <i>Vox Sanguinis</i> , 2009 , 11, 326-331	3.1	11
94	Molecular targeted therapies for solid tumors: management of side effects. <i>Oncology Research and Treatment</i> , 2009 , 32, 129-38	2.8	10
93	High response to docetaxel (D)/carboplatin (C) based chemotherapy as salvage therapy in patients with docetaxel-resistant metastatic hormone-refractory prostate cancer (HRPC). <i>Journal of Clinical Oncology</i> , 2009 , 27, e16041-e16041	2.2	
92	Association of therapy with sunitinib and treatment-related hyperparathyroidism in renal cell carcinoma. <i>Journal of Clinical Oncology</i> , 2009 , 27, e16023-e16023	2.2	
91	Novel therapies in advanced renal cell carcinoma: management of adverse events from sorafenib and sunitinib. <i>Deutsches A&#x0308;rzteblatt International</i> , 2008 , 105, 232-7	2.5	12
90	Nierenzellkarzinom. <i>Best Practice Onkologie</i> , 2007 , 2, 4-13	0	
89	Comparison of amino acid compositions of peptides eluted from HLA-B27 molecules of healthy individuals and patients with ankylosing spondylitis. <i>Immunology Letters</i> , 2006 , 103, 135-41	4.1	4
88	PROLONGED SURVIVAL OF MATERNAL SKIN GRAFTS IN NEWBORN RABBITS. <i>Annals of the New York Academy of Sciences</i> , 2006 , 129, 234-240	6.5	3
87	Identification of novel regulators in T-cell differentiation of aplastic anemia patients. <i>BMC Genomics</i> , 2006 , 7, 263	4.5	14
86	Sexual dimorphism, but not testosterone itself, is responsible for ankylosing enthesitis of the ankle in B10.BR (H-2k) male mice. <i>Annals of the Rheumatic Diseases</i> , 2006 , 65, 130-2	2.4	5
85	Therapie des Nierenzellkarzinoms. <i>Onkologie</i> , 2006 , 12, 1153-1168	0.1	0
84	Antigen-recognition sites of micromanipulated T cells in patients with acquired aplastic anemia. <i>Experimental Hematology</i> , 2005 , 33, 804-10	3.1	3
83	Inflammatory pseudotumor of the lung following invasive aspergillosis in a patient with chronic graft-vs.-host disease. <i>European Journal of Haematology</i> , 2005 , 75, 68-72	3.8	21
82	Regulation of T Cell Homeostasis and Cell Cycling in Patients with Acute Myeloid Leukemia.. <i>Blood</i> , 2005 , 106, 2767-2767	2.2	
81	Germ-free mice do not develop ankylosing enthesopathy, a spontaneous joint disease. <i>Human Immunology</i> , 2000 , 61, 555-8	2.3	66
80	Strong association of HLA-B27 heavy chain with beta 2-microglobulin. <i>Human Immunology</i> , 2000 , 61, 1197-201	2.3	9
79	Histopathology of murine ankylosing enthesopathy. <i>Pathology Research and Practice</i> , 1998 , 194, 797-803	3.4	19

78	Solitary caging protects mice from ankylosing enthesopathy. <i>Clinical Rheumatology</i> , 1996 , 15 Suppl 1, 32-3	3.9	5
77	Grouped caging predisposes male mice to ankylosing enthesopathy. <i>Annals of the Rheumatic Diseases</i> , 1996 , 55, 645-7	2.4	16
76	Maternal age influences risk for HLA-B27 associated ankylosing enthesopathy in transgenic mice. <i>Annals of the Rheumatic Diseases</i> , 1995 , 54, 754-6	2.4	12
75	Estimates of cytotoxic T-lymphocyte precursor frequencies against HLA class I antigens in responder-stimulator pairs with a negative mixed lymphocyte culture reaction. <i>Human Immunology</i> , 1995 , 44, 97-102	2.3	1
74	Self-restricted primary human histocompatibility leukocyte antigen (HLA)-specific cytotoxic T lymphocytes. <i>International Immunology</i> , 1993 , 5, 103-7	4.9	13
73	Immunogenetics of the spondyloarthropathies. <i>Current Opinion in Rheumatology</i> , 1993 , 5, 436-45	5.3	10
72	Absence of autoantibodies to peptides shared by HLA-B27.5 and <i>Klebsiella pneumoniae</i> nitrogenase in serum samples from HLA-B27 positive patients with ankylosing spondylitis and Reiter's syndrome. <i>Annals of the Rheumatic Diseases</i> , 1992 , 51, 783-9	2.4	24
71	H-2 influence on ankylosing enthesopathy of the ankle (ANKENT). <i>Folia Biologica</i> , 1992 , 38, 258-62	0.7	5
70	Frequency analysis of HLA-specific cytotoxic T lymphocyte precursors in humans. <i>Transplantation</i> , 1991 , 51, 1096-103	1.8	16
69	A subpopulation of mouse cytotoxic T lymphocytes recognizes allogeneic H-2 class I antigens in the context of other H-2 class I molecules. <i>Journal of Experimental Medicine</i> , 1991 , 174, 15-9	16.6	22
68	Dysfunction of HLA-B27. <i>Scandinavian Journal of Rheumatology</i> , 1990 , 87, 51-69; discussion 69	1.9	13
67	Variations in the T-cell repertoire against HLA antigens in humans. <i>Human Immunology</i> , 1990 , 27, 1-15	2.3	13
66	Specificity and frequency of primary anti-HLA cytotoxic T lymphocytes in normal and HLA-B27.2-, HLA-B27.5-, and HLA-Cw3-transgenic mice. A transgenic model for MHC xenoantigen recognition. <i>Journal of Immunology</i> , 1990 , 144, 4513-9	5.3	10
65	HLA expression and function in single and double HLA-B27-transgenic mice. <i>Tissue Antigens</i> , 1989 , 34, 50-63		15
64	Immunization with syngeneic Sendai virus-infected cells induce no MHC-restricted antibodies but antibodies specific for H-2 class I determinants. <i>Immunogenetics</i> , 1989 , 29, 108-11	3.2	4
63	Recognition of xeno-(HLA, SLA) major histocompatibility complex antigens by mouse cytotoxic T cells is not H-2 restricted: a study with transgenic mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1989 , 86, 617-20	11.5	34
62	Individual Differences Among Syngeneic Mice in Immune Response to Alloantigens and Modified Self-MHC-Antigens 1989 , 122-133		
61	Different linkage disequilibria of HLA-B27 subtypes and HLA-C locus alleles. <i>Tissue Antigens</i> , 1988 , 32, 74-7		11

60 Naturally Occurring H-2 Specific Antibodies **1988**, 7-13

59	Distribution of HLA-B27 subtypes in patients with ankylosing spondylitis: the disease is associated with a common determinant of the various B27 molecules. <i>Annals of the Rheumatic Diseases</i> , 1987 , 46, 353-6	2.4	91
58	Conventional alloantisera can recognize the same HLA-B27 polymorphism as detected by cytotoxic T lymphocytes. <i>Human Immunology</i> , 1987 , 20, 265-71	2.3	15
57	Induction of H-2-specific antibodies by injections of syngeneic Sendai virus-coated cells. <i>European Journal of Immunology</i> , 1987 , 17, 27-35	6.1	27
56	HLA-restricted recognition of viral antigens in HLA transgenic mice. <i>Nature</i> , 1987 , 329, 447-9	50.4	83
55	Natural autoreactive H-2-specific serum antibodies in a group of BALB/cBy (H-2d) mice. <i>Tissue Antigens</i> , 1986 , 27, 106-11		5
54	Evidence for a regulatory role of the T8 (CD8) antigen in antigen-specific and anti-T3-(CD3)-induced lytic activity of allospecific cytotoxic T lymphocyte clones. <i>European Journal of Immunology</i> , 1986 , 16, 1363-71	6.1	34
53	Polymorphic and autoreactive H-2-specific monoclonal antibody isolated after injections of syngeneic Sendai virus-coated lymphocytes. <i>Immunogenetics</i> , 1986 , 24, 402-8	3.2	12
52	Anti-MHC immunity detected prior to intentional alloimmunization. IV. Natural monoclonal H-2-specific antibodies. <i>International Journal of Immunogenetics</i> , 1986 , 13, 287-97		7
51	Individual differences in the cytotoxic T-lymphocyte response in man to public HLA determinants. <i>Cellular Immunology</i> , 1986 , 103, 252-71	4.4	6
50	Fine specificity of human HLA-B7-specific cytotoxic T-lymphocyte clones. I. Identification of HLA-B7 subtypes and histotopes of the HLA-B7 cross-reacting group. <i>Human Immunology</i> , 1986 , 16, 375-89	2.3	22
49	An improved biochemical method for the analysis of HLA-class I antigens. Definition of new HLA-class I subtypes. <i>Human Immunology</i> , 1986 , 16, 169-81	2.3	159
48	Blind confirmation in Leiden of Geczy factor on the cells of Dutch patients with ankylosing spondylitis. <i>Human Immunology</i> , 1986 , 17, 239-45	2.3	18
47	Identification of new B27 subtypes (B27C and B27D) prevalent in oriental populations. <i>Human Immunology</i> , 1986 , 16, 163-8	2.3	45
46	Cross-reactions of Class II Histocompatibility Antigens of Various Species 1986 , 128-153		2
45	Frequency of naturally occurring H-2-specific antibodies in mouse sera monitored by "superreactive" rabbit complement. <i>Tissue Antigens</i> , 1985 , 26, 259-61		4
44	Anti-MHC immunity detected prior to intentional alloimmunization. III. Natural autoreactive H-2-specific antibodies. <i>Immunogenetics</i> , 1985 , 21, 491-504	3.2	12
43	Blind confirmation of Geczy factor in ankylosing spondylitis. <i>Lancet, The</i> , 1985 , 2, 943-4	40	18

42	Activation of cytotoxic T lymphocytes in HLA-A, -B and -C-identical responder-stimulator pairs. I. Variations in generation of anti-class-II CTL in primary mixed lymphocyte cultures. <i>Tissue Antigens</i> , 1984 , 24, 81-9		7
41	Activation of cytotoxic T lymphocytes in HLA-A, -B and -C-identical responder-stimulator pairs. II. New subtypes of HLA-Bw35. <i>Tissue Antigens</i> , 1984 , 24, 90-7		12
40	A cloned cytotoxic T-lymphocyte (CTL) line recognizing a subtype of HLA B27. <i>Human Immunology</i> , 1984 , 9, 231-42	2.3	19
39	B27 Subtypes 1984 , 418-419		4
38	Heterogeneity of HLA-B7 as Detected by Cytotoxic T Cell Clones 1984 , 479-480		1
37	Antigen Report: HLA-B27 1984 , 144-144		5
36	Allo-immune anti-Iak sera of individual mice detect HLA-DR-associated polymorphism on human B cells. <i>Tissue Antigens</i> , 1983 , 22, 134-41		1
35	A search for association of HLA antigens with paranoid schizophrenia. A9 appears as a possible marker. <i>Tissue Antigens</i> , 1983 , 22, 186-93		28
34	Specificity of anti-HLA-B27 cytotoxic T lymphocytes. <i>Tissue Antigens</i> , 1983 , 22, 267-82		19
33	Biochemical analysis of variant HLA-B27 antigens. <i>Human Immunology</i> , 1983 , 6, 111-7	2.3	49
32	Naturally occurring cytotoxic human antibodies recognize H-2-controlled murine lymphocyte antigens. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1983 , 80, 4479-83	11.5	3
31	Subtypes of HLA-B27 detected by cytotoxic T lymphocytes and their role in self-recognition. <i>Human Immunology</i> , 1982 , 5, 259-68	2.3	83
30	Natural H-2-specific antibodies in sera of aged mice. <i>Immunogenetics</i> , 1982 , 15, 95-102	3.2	22
29	Human Ia molecules carrying DC1 or BR4X7 determinants are not homologous to murine I-E molecules. <i>Immunogenetics</i> , 1982 , 16, 187-99	3.2	6
28	In vitro-isolated human cytotoxic T-lymphocyte clones detect variations in serologically defined HLA antigens. <i>Immunogenetics</i> , 1982 , 16, 503-12	3.2	40
27	Identification of human CML target. HLA-B locus (B12) antigen variants defined by CTL generated between B locus-identical (B12) responder-stimulator pairs. <i>Journal of Immunology</i> , 1982 , 128, 949-55	5.3	34
26	Fine specificity of cytotoxic T lymphocytes directed against H-2Ld. <i>Immunogenetics</i> , 1981 , 12, 75-88	3.2	6
25	Constancy of cross-reactivity patterns in sera of individual mice during the anti-H-2 response. <i>Tissue Antigens</i> , 1980 , 16, 49-55		1

24	Anti-H-2 antibodies induced by syngeneic immunization. <i>Immunogenetics</i> , 1980 , 10, 319-32	3.2	25
23	Unexpected lympho-cytotoxic reactions of anti-H-2 sera on normal lymph-node cells: are they due to altered H-2 structures or anti-viral antibodies?. <i>International Journal of Immunogenetics</i> , 1980 , 7, 91-7		5
22	Lymphocytotoxic antibodies produced by H-2 allo-immunisation distinguish between MuLV-positive and -negative substrains of the same H-2 haplotype. <i>Nature</i> , 1979 , 282, 843-5	50.4	15
21	Cross-reactivity among the products of three nonallelic H-2 loci, H-2Ld, H-2Dq, and H-2Kk. <i>Transplantation</i> , 1979 , 28, 339-42	1.8	17
20	Individual mice recognize the complex nature of H-2 antigens; unexpected reactions (anti-Kk) in anti-BALB/c-H-2d sera produced in the BALB/c-H-2db mutant. <i>Transplantation Proceedings</i> , 1979 , 11, 642-6	1.1	12
19	A syngeneic anti tumor serum recognizing a complex H-2 alloantigen. <i>Immunobiology</i> , 1979 , 156, 110-20	3.4	5
18	Anti-H-2Dd antibodies cross-react with HLA-A11 and Aw31. <i>Tissue Antigens</i> , 1978 , 11, 439-42		4
17	HLA antigens as possible markers of heterogeneity in schizophrenia. <i>International Journal of Immunogenetics</i> , 1978 , 5, 165-72		20
16	Individual mice of one inbred strain produce anti-H-2 and anti-HLA antibodies of different specificities. <i>Tissue Antigens</i> , 1978 , 12, 32-8		23
15	HLA-Cw4 in paranoid schizophrenia. <i>Tissue Antigens</i> , 1977 , 9, 41-4		14
14	Cytotoxic effect of anti-H-2 and anti-Ia antisera on human B and T cells. <i>Scandinavian Journal of Immunology</i> , 1977 , 6, 431-7	3.4	14
13	HLA antigens in schizophrenia. <i>Tissue Antigens</i> , 1976 , 8, 217-20		22
12	HL-A ANTIGENS IN JUVENILE RHEUMATOID ARTHRITIS. <i>International Journal of Immunogenetics</i> , 1976 , 3, 229-236		4
11	HL-A antigens in aged persons. <i>Tissue Antigens</i> , 1975 , 6, 269-71		27
10	Genetic studies on male sterility of hybrids between laboratory and wild mice (<i>Mus musculus</i> L.). <i>Genetical Research</i> , 1974 , 24, 189-206	1.1	165
9	Sex-dependent and H-2-linked influence on expressivity of the brachyury gene in mice. <i>Journal of Heredity</i> , 1974 , 65, 369-72	2.4	23
8	Relations of HL-A and Rh Systems to Immune Reactivity. <i>Vox Sanguinis</i> , 1974 , 26, 470-482	3.1	27
7	Genetic association between H-2 gene and testosterone metabolism in mice. <i>Nature: New Biology</i> , 1972 , 238, 280-1		70

6	Histocompatibility gene organization and mixed lymphocyte reaction. <i>Nature: New Biology</i> , 1971 , 230, 271-2		20
5	Testosterone and testosterone binding in murine plasma. <i>Steroidologia</i> , 1971 , 2, 113-20		11
4	The major histocompatibility antigens in various species. <i>Current Topics in Microbiology and Immunology</i> , 1970 , 53, 1-90	3.3	14
3	Allo-Antigens and Antigenic Factors of Human Leukocytes. <i>Vox Sanguinis</i> , 1966 , 11, 326-331	3.1	18
2	Allo-antigens and antigenic factors of human leukocytes. A hypothesis. <i>Vox Sanguinis</i> , 1966 , 11, 326-31	3.1	7
1	The Prognostic Impact of PD-L2 in Papillary Renal-Cell Carcinoma. <i>Urologia Internationalis</i> , 1-9	1.9	0